Not every Phase I SBIR leads to Phase II. The transition requires a deliberate strategy — technically, commercially, and administratively. Here's how to maximize your chances of a successful Phase II award.
Understanding the transition: Phase I proves feasibility. Phase II funds full R&D toward a commercializable product. The evaluation criteria shift significantly: Phase II reviewers want to see not just technical merit but a credible, near-term path to market.
What strengthens a Phase II application: • Phase I results that exceeded expectations — not just "we showed it's feasible" but "here's the data that proves it." • Letters of intent from potential customers, pilot partners, or licensees. A signed LOI carries far more weight than a letter of support. • Revenue or contracts already in place — any commercialization traction dramatically strengthens the application. • A named business development partner or commercial advisor. • A realistic manufacturing or scaling plan.
Common Phase I-to-II failure modes: • Technical success without commercial progress — you hit all your technical milestones but never talked to customers. • A commercialization plan copy-pasted from Phase I without updates. • Missing the deadline — know your Phase II submission window. It varies by agency. • Scope creep — Phase II should be a direct, scaled continuation of Phase I, not a pivot.
SBIR Phase II commercialization requirements: • DoD SBIR Phase II requires a detailed Transition Plan. • NIH SBIR Phase II requires a Commercialization Plan (3 pages) including market analysis, competition, and financing strategy. • NSF SBIR Phase II requires a Go-to-Market section with specific milestones and financial projections.
After Phase II: • Phase IIB / Phase III is non-SBIR follow-on (private investment, government contracts, licensing). • Some agencies offer Phase IIB Bridge awards for companies with matching private investment.